Momenta Pharmaceuticals' (NASDAQ: MNTA) fourth-quarter earnings were about as rough as the rest of its 2018, a year in which the biotech needed to restructure and cut about half its workforce.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,